메뉴 건너뛰기




Volumn 27, Issue 12, 2012, Pages 2419-2428

Erratum: Safety of osteoanabolic therapy: A decade of experience (Journal of Bone and Mineral Research (2012) 27:12 (2419-2428) DOI: 10.1002/jbmr.1800);Safety of osteoanabolic therapy: A decade of experience

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; DENOSUMAB; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; VITAMIN D;

EID: 84869453613     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1837     Document Type: Erratum
Times cited : (124)

References (92)
  • 1
    • 77954254610 scopus 로고    scopus 로고
    • National Osteoporosis Foundation Washington. DC: National Osteoporosis Foundation
    • National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington. DC: National Osteoporosis Foundation. 2010.
    • (2010) Clinician's Guide to Prevention and Treatment of Osteoporosis
  • 2
    • 0036001310 scopus 로고    scopus 로고
    • Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
    • Vahle JL, Masahiko S, Long GG, Young JK, Francis PC, Englehardt JA, Westmore MS, Ma YL, Nold JB., Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30: 312.
    • (2002) Toxicol Pathol. , vol.30 , pp. 312
    • Vahle, J.L.1    Masahiko, S.2    Long, G.G.3    Young, J.K.4    Francis, P.C.5    Englehardt, J.A.6    Westmore, M.S.7    Ma, Y.L.8    Nold, J.B.9
  • 5
    • 26844521277 scopus 로고    scopus 로고
    • Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
    • Bellido T, Ali AA, Gubrij I, Potkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL., Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146 (11): 4577-83.
    • (2005) Endocrinology. , vol.146 , Issue.11 , pp. 4577-4583
    • Bellido, T.1    Ali, A.A.2    Gubrij, I.3    Potkin, L.I.4    Fu, Q.5    O'Brien, C.A.6    Manolagas, S.C.7    Jilka, R.L.8
  • 6
    • 0037591085 scopus 로고    scopus 로고
    • The cellular and clinical parameters of anabolic therapy for osteoporosis
    • Rosen CJ., The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gen Expr. 2003; 13 (1): 25-38.
    • (2003) Crit Rev Eukaryot Gen Expr. , vol.13 , Issue.1 , pp. 25-38
    • Rosen, C.J.1
  • 7
    • 17144383676 scopus 로고    scopus 로고
    • Identifying genes that regulate bone remodeling as potential therapeutic targets
    • Krane SM., Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med. 2005; 201 (6): 841-3.
    • (2005) J Exp Med. , vol.201 , Issue.6 , pp. 841-843
    • Krane, S.M.1
  • 8
    • 3242667700 scopus 로고    scopus 로고
    • Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone. (1-34)
    • Buxton EC, Yao W, Lane NE., Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone. (1-34). J Clin Endocrinol Metab. 2004; 89 (7): 3332-6.
    • (2004) J Clin Endocrinol Metab. , vol.89 , Issue.7 , pp. 3332-3336
    • Buxton, E.C.1    Yao, W.2    Lane, N.E.3
  • 9
    • 44849121708 scopus 로고    scopus 로고
    • Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window
    • Bilezikian JP., Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008; 6 (1): 24-38.
    • (2008) Curr Osteoporos Rep. , vol.6 , Issue.1 , pp. 24-38
    • Bilezikian, J.P.1
  • 10
    • 0026657511 scopus 로고
    • Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone
    • Bradbeer JN, Arlot ME, Meunier PJ, Reeve J., Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol. 1992; 37: 282-9.
    • (1992) Clin Endocrinol. , vol.37 , pp. 282-289
    • Bradbeer, J.N.1    Arlot, M.E.2    Meunier, P.J.3    Reeve, J.4
  • 11
    • 0033926149 scopus 로고    scopus 로고
    • Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis
    • Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH., Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone. 2000; 27 (2): 311-8.
    • (2000) Bone. , vol.27 , Issue.2 , pp. 311-318
    • Hodsman, A.B.1    Kisiel, M.2    Adachi, J.D.3    Fraher, L.J.4    Watson, P.H.5
  • 12
    • 57449090596 scopus 로고    scopus 로고
    • Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone. 1-84
    • Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA., Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone. 1-84. Bone. 2009; 44: 13-9.
    • (2009) Bone. , vol.44 , pp. 13-19
    • Recker, R.R.1    Bare, S.P.2    Smith, S.Y.3    Varela, A.4    Miller, M.A.5    Morris, S.A.6
  • 13
    • 0025753221 scopus 로고
    • Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
    • Hodsman AB, Steer BM, Fraher LJ, Drost DJ., Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 1991; 14: 67-83.
    • (1991) Bone Miner. , vol.14 , pp. 67-83
    • Hodsman, A.B.1    Steer, B.M.2    Fraher, L.J.3    Drost, D.J.4
  • 17
    • 0242413030 scopus 로고    scopus 로고
    • Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure
    • Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF., Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932-41.
    • (2003) J Bone Miner Res. , vol.18 , pp. 1932-1941
    • Jiang, Y.1    Zhao, J.J.2    Mitlak, B.H.3    Wang, O.4    Genant, H.K.5    Eriksen, E.F.6
  • 18
    • 0002651961 scopus 로고    scopus 로고
    • Assessment of effects of ly333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital x-ray radiogrammetry
    • Hyldstrup L, Jorgensen JT, Gaich G., Assessment of effects of ly333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital x-ray radiogrammetry. Bone. 2002; 28: S97.
    • (2002) Bone. , vol.28
    • Hyldstrup, L.1    Jorgensen, J.T.2    Gaich, G.3
  • 21
    • 84856108386 scopus 로고    scopus 로고
    • Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: Meta-analysis of randomised controlled trials
    • Han SL, Wan SL., Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012; 66 (2): 199-209.
    • (2012) Int J Clin Pract. , vol.66 , Issue.2 , pp. 199-209
    • Han, S.L.1    Wan, S.L.2
  • 23
    • 84877948489 scopus 로고    scopus 로고
    • Treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of a 2007 report [Internet]
    • AHRQ Publication No. 12-EHC023-EF Prepared by Southern California Evidence-based Practice Center-RAND Corporation, Santa Monica, CA, under Contract No. HHSA-290-2007-1006 2-I. Rockville, MD: Agency for Healthcare Research and Quality; 2012 Mar [cited 2012 Oct 18]
    • Crandall CC, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG., Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report [Internet]. Comparative Effectiveness Review No. 53. AHRQ Publication No. 12-EHC023-EF Prepared by Southern California Evidence-based Practice Center-RAND Corporation, Santa Monica, CA, under Contract No. HHSA-290-2007-1006 2-I. Rockville, MD: Agency for Healthcare Research and Quality; 2012 Mar [cited 2012 Oct 18]. Available from. http:// effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction= displayproduct&productid=1006.
    • Comparative Effectiveness Review No. 53
    • Crandall, C.C.1    Newberry, S.J.2    Gellad, W.G.3    Diamant, A.4    Lim, Y.W.5    Suttorp, M.6    Motala, A.7    Ewing, B.8    Roth, B.9    Timmer, M.10    Shanman, R.11    Shekelle, P.G.12
  • 24
    • 0033550968 scopus 로고    scopus 로고
    • Mortality after all major types of osteoporotic fracture in men and women: An observational study
    • Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA., Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353 (9156): 878-82.
    • (1999) Lancet. , vol.353 , Issue.9156 , pp. 878-882
    • Center, J.R.1    Nguyen, T.V.2    Schneider, D.3    Sambrook, P.N.4    Eisman, J.A.5
  • 25
    • 0033710488 scopus 로고    scopus 로고
    • Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
    • Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP., Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endrocrinol Metab. 2000; 85 (9): 3069-76.
    • (2000) J Clin Endrocrinol Metab. , vol.85 , Issue.9 , pp. 3069-3076
    • Kurland, E.S.1    Cosman, F.2    McMahon, D.J.3    Rosen, C.J.4    Lindsay, R.5    Bilezikian, J.P.6
  • 27
    • 22844447275 scopus 로고    scopus 로고
    • Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy
    • Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH., Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis Int. 2005; 16 (5): 510-6.
    • (2005) Osteoporosis Int. , vol.16 , Issue.5 , pp. 510-516
    • Kaufman, J.M.1    Orwoll, E.2    Goemaere, S.3    San Martin, J.4    Hossain, A.5    Dalsky, G.P.6    Lindsay, R.7    Mitlak, B.H.8
  • 29
    • 70350555320 scopus 로고    scopus 로고
    • Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial
    • Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60 (11): 3346-55.
    • (2009) Arthritis Rheum. , vol.60 , Issue.11 , pp. 3346-3355
    • Saag, K.G.1    Zanchetta, J.R.2    Devogelaer, J.P.3    Adler, R.A.4    Eastell, R.5    See, K.6    Krege, J.H.7    Krohn, K.8    Warner, M.R.9
  • 30
  • 32
    • 77958131700 scopus 로고    scopus 로고
    • Treatment of postmenopausal women with osteoporosis with PTH (1-84) for 36 months: Treatment extension study
    • Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W., Treatment of postmenopausal women with osteoporosis with PTH (1-84) for 36 months: treatment extension study. Curr Med Res Opin. 2010; 26 (11): 2627-33.
    • (2010) Curr Med Res Opin. , vol.26 , Issue.11 , pp. 2627-2633
    • Zanchetta, J.R.1    Bogado, C.E.2    Cisari, C.3    Aslanidis, S.4    Greisen, H.5    Fox, J.6    Lems, W.7
  • 33
    • 15944389876 scopus 로고    scopus 로고
    • Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures
    • Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH., Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005; 90 (3): 1583-7.
    • (2005) J Clin Endocrinol Metab. , vol.90 , Issue.3 , pp. 1583-1587
    • Gallagher, J.C.1    Genant, H.K.2    Crans, G.G.3    Vargas, S.J.4    Krege, J.H.5
  • 35
    • 33846447882 scopus 로고    scopus 로고
    • Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
    • Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH., Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21 (11): 1785-90.
    • (2006) J Bone Miner Res. , vol.21 , Issue.11 , pp. 1785-1790
    • Chen, P.1    Miller, P.D.2    Delmas, P.D.3    Misurski, D.A.4    Krege, J.H.5
  • 37
    • 0029798867 scopus 로고    scopus 로고
    • Synthetic human parathyroid hormone 1-34. vs calcitriol,calcium in the treatment of hypoparathyroidism
    • Winer KK, Yanovski JA, Cutler GB Jr., Synthetic human parathyroid hormone 1-34. vs calcitriol,calcium in the treatment of hypoparathyroidism. JAMA. 1996; 276: 631-6.
    • (1996) JAMA , vol.276 , pp. 631-636
    • Winer, K.K.1    Yanovski, J.A.2    Cutler, Jr.G.B.3
  • 38
    • 0031773242 scopus 로고    scopus 로고
    • Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone. 1-34 in treatment of hypoparathyroidism
    • Winer KK, Yanovski JA, Sarani B., Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone. 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998; 83: 3480-6.
    • (1998) J Clin Endocrinol Metab. , vol.83 , pp. 3480-3486
    • Winer, K.K.1    Yanovski, J.A.2    Sarani, B.3
  • 40
    • 84863029403 scopus 로고    scopus 로고
    • Synthetic human parathyroid hormone. 1-34. replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism
    • Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS., Cutler GB Jr., Synthetic human parathyroid hormone. 1-34. replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97 (2): 391-9.
    • (2012) J Clin Endocrinol Metab. , vol.97 , Issue.2 , pp. 391-399
    • Winer, K.K.1    Zhang, B.2    Shrader, J.A.3    Peterson, D.4    Smith, M.5    Albert, P.S.6    Cutler, Jr.G.B.7
  • 41
    • 80053185721 scopus 로고    scopus 로고
    • The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study
    • Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L., and the hypoparathyroid study group. The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26: 2358-70.
    • (2011) J Bone Miner Res. , vol.26 , pp. 2358-2370
    • Sikjaer, T.1    Rejnmark, L.2    Rolighed, L.3    Heickendorff, L.4    Mosekilde, L.5
  • 45
    • 84869389652 scopus 로고    scopus 로고
    • Effect of recombinant human parathyroid hormone (rhPTH[1-84]) on skeletal dynamics and BMD in hypoparathyroidism: The REPLACE study
    • October 11-26; Minneapolis, MN, USA
    • Bilezikian J, Clarke BL, Mannstadt M, Vokes TJ, Shoback D, Lagast H, Garceau R., Effect of recombinant human parathyroid hormone (rhPTH[1-84]) on skeletal dynamics and BMD in hypoparathyroidism: the REPLACE study. Presented at the ASBMR Annual Meeting;. 2012 October 11-26; Minneapolis, MN, USA.
    • (2012) Presented at the ASBMR Annual Meeting;.
    • Bilezikian, J.1    Clarke, B.L.2    Mannstadt, M.3    Vokes, T.J.4    Shoback, D.5    Lagast, H.6    Garceau, R.7
  • 46
    • 84869459492 scopus 로고    scopus 로고
    • Treatment of hypoparathyroidism with PTH (1-84) is safe and effective for up to 4 years
    • September 16-20; San Diego, CA, USA
    • Cusano N, Rubin M, Ives R, Sliney J Jr, Bilezikian J., Treatment of hypoparathyroidism with PTH (1-84) is safe and effective for up to 4 years. Presented at the ASBMR Annual Meeting;. 2011 September 16-20; San Diego, CA, USA.
    • (2011) Presented at the ASBMR Annual Meeting;.
    • Cusano, N.1    Rubin, M.2    Ives, R.3    Sliney, Jr.J.4    Bilezikian, J.5
  • 50
    • 80052871434 scopus 로고    scopus 로고
    • Parathyroid hormone. 1-84. accelerates fracture-healing in pubic bones of elderly osteoporotic women
    • Sep 7
    • Peichl P, Holzer LA, Maier R, Holzer G., Parathyroid hormone. 1-84. accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011 Sep 7; 93 (17): 1583-7.
    • (2011) J Bone Joint Surg Am. , vol.93 , Issue.17 , pp. 1583-1587
    • Peichl, P.1    Holzer, L.A.2    Maier, R.3    Holzer, G.4
  • 51
    • 84870782274 scopus 로고    scopus 로고
    • NIH ClinicalTrials gov identifier: NCT01473589 Bethesda, MD: NIH; 2012 [cited. 2012 Oct 18]
    • NIH ClinicalTrials gov identifier: NCT01473589. Effect of Teriparatide on Hip Fracture Healing [Internet]. Bethesda, MD: NIH; 2012 [cited. 2012 Oct 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT01473589.
    • Effect of Teriparatide on Hip Fracture Healing [Internet]
  • 52
    • 80052540017 scopus 로고    scopus 로고
    • Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide
    • Sep
    • Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F., Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011 Sep; 96 (9): 2675-80.
    • (2011) J Clin Endocrinol Metab. , vol.96 , Issue.9 , pp. 2675-2680
    • Carvalho, N.N.1    Voss, L.A.2    Almeida, M.O.3    Salgado, C.L.4    Bandeira, F.5
  • 53
    • 33847339685 scopus 로고    scopus 로고
    • Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]
    • Mar
    • Harper RP, Fung E., Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007 Mar; 65 (3): 573-80.
    • (2007) J Oral Maxillofac Surg. , vol.65 , Issue.3 , pp. 573-580
    • Harper, R.P.1    Fung, E.2
  • 54
    • 68849132188 scopus 로고    scopus 로고
    • Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy
    • Aug
    • Lau AN, Adachi JD., Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009 Aug; 36 (8): 1835-7.
    • (2009) J Rheumatol. , vol.36 , Issue.8 , pp. 1835-1837
    • Lau, A.N.1    Adachi, J.D.2
  • 55
    • 3242887547 scopus 로고    scopus 로고
    • Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
    • Jul-Aug
    • Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M., Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004 Jul-Aug; 32 (4): 426-38.
    • (2004) Toxicol Pathol. , vol.32 , Issue.4 , pp. 426-438
    • Vahle, J.L.1    Long, G.G.2    Sandusky, G.3    Westmore, M.4    Ma, Y.L.5    Sato, M.6
  • 56
    • 44449104186 scopus 로고    scopus 로고
    • Perspective on the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PT. H(1-84)
    • Jun
    • Tashjian AH, Goltzman D., Perspective on the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PT. H(1-84). J Bone Miner Res. 2008 Jun; 23 (6): 803-10.
    • (2008) J Bone Miner Res. , vol.23 , Issue.6 , pp. 803-810
    • Tashjian, A.H.1    Goltzman, D.2
  • 57
    • 66149135224 scopus 로고    scopus 로고
    • International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons
    • Jul
    • Mirabello L, Troisi RJ, Savage SA., International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009 Jul; 125 (1): 229-34.
    • (2009) Int J Cancer. , vol.125 , Issue.1 , pp. 229-234
    • Mirabello, L.1    Troisi, R.J.2    Savage, S.A.3
  • 58
    • 79955086282 scopus 로고    scopus 로고
    • Using epidemiology and genomics to understand osteosarcoma etiology
    • Savage SA, Mirabello L., Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011; 2011: 548151.
    • (2011) Sarcoma. , vol.2011 , pp. 548151
    • Savage, S.A.1    Mirabello, L.2
  • 59
    • 63449118087 scopus 로고    scopus 로고
    • Osteosarcoma incidence and survival rates from. 1973 to 2004: Data from the Surveillance
    • Apr
    • Mirabello L, Troisi RJ, Savage SA., Osteosarcoma incidence and survival rates from. 1973 to 2004: data from the Surveillance. Epidemiology, and End Results Program. Cancer. 2009; Apr; 115 (7): 1531-43.
    • (2009) Epidemiology, and End Results Program. Cancer. , vol.115 , Issue.7 , pp. 1531-1543
    • Mirabello, L.1    Troisi, R.J.2    Savage, S.A.3
  • 60
    • 84870796024 scopus 로고    scopus 로고
    • U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Rockville, MD: Center for Drug Evaluation and Research 2000 May 19 [cited. 2012 Oct 18]
    • U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Development of parathyroid hormone for the prevention and treatment of osteoporosis. Draft guidance. Rockville, MD: Center for Drug Evaluation and Research 2000 May 19 [cited. 2012 Oct 18]. Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071618.pdf.
    • Guidance for Industry. Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis. Draft Guidance
  • 62
    • 0035137942 scopus 로고    scopus 로고
    • Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)
    • Feb
    • Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R., Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 2001 Feb; 28 (2): 150-9.
    • (2001) Bone. , vol.28 , Issue.2 , pp. 150-159
    • Jerome, C.P.1    Burr, D.B.2    Van Bibber, T.3    Hock, J.M.4    Brommage, R.5
  • 64
    • 56749181173 scopus 로고    scopus 로고
    • Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]
    • Dec
    • Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M., Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res. 2008 Dec; 23 (12): 2033-9.
    • (2008) J Bone Miner Res. , vol.23 , Issue.12 , pp. 2033-2039
    • Vahle, J.L.1    Zuehlke, U.2    Schmidt, A.3    Westmore, M.4    Chen, P.5    Sato, M.6
  • 66
    • 33846477811 scopus 로고    scopus 로고
    • Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine
    • Feb
    • Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY., Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res. 2007 Feb; 22 (2): 260-73.
    • (2007) J Bone Miner Res. , vol.22 , Issue.2 , pp. 260-273
    • Fox, J.1    Miller, M.A.2    Newman, M.K.3    Turner, C.H.4    Recker, R.R.5    Smith, S.Y.6
  • 67
    • 84869413759 scopus 로고    scopus 로고
    • The US Postmarketing Surveillance Study of Adult Osteosarcoma Teriparatide study design findings from the first 7 years
    • Andrews E, Gilsenan A, Midkiff K, Sherril B, Wu Y, Mann B, Masica D., The US Postmarketing Surveillance Study of Adult Osteosarcoma Teriparatide study design findings from the first 7 years. JBMR. 2012 27.
    • (2012) JBMR , vol.27
    • Andrews, E.1    Gilsenan, A.2    Midkiff, K.3    Sherril, B.4    Wu, Y.5    Mann, B.6    Masica, D.7
  • 70
    • 84869432427 scopus 로고    scopus 로고
    • Case report: Osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting
    • 24)
    • Lubitz R, Prasad S., Case report: osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting. J Bone Miner Res. 2009; 24 (Suppl 1): SU0354.
    • (2009) J Bone Miner Res. , Issue.SUPPL. 1
    • Lubitz, R.1    Prasad, S.2
  • 71
    • 77953438185 scopus 로고    scopus 로고
    • Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH(1-84) in the treatment of postmenopausal osteoporosis
    • Pietrogrande L., Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH(1-84) in the treatment of postmenopausal osteoporosis. Int J Womens Health. 2009; 1: 193-203.
    • (2009) Int J Womens Health. , vol.1 , pp. 193-203
    • Pietrogrande, L.1
  • 72
    • 0035991225 scopus 로고    scopus 로고
    • Commentary on clinical safety of recombinant human parathyroid hormone. 1-34 in the treatment of osteoporosis in men and postmenopausal women
    • Jul
    • Tashjian AH Jr, Chabner BA., Commentary on clinical safety of recombinant human parathyroid hormone. 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 2002 Jul; 17 (7): 1151-61.
    • (2002) J Bone Miner Res. , vol.17 , Issue.7 , pp. 1151-1161
    • Tashjian, Jr.A.H.1    Chabner, B.A.2
  • 74
    • 84933876926 scopus 로고
    • On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol
    • Selye H., On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology. 1932; 16: 547-58.
    • (1932) Endocrinology. , vol.16 , pp. 547-558
    • Selye, H.1
  • 77
    • 78649328893 scopus 로고    scopus 로고
    • Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis
    • Dec
    • Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H., Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010 Dec; 87 (6): 485-92.
    • (2010) Calcif Tissue Int. , vol.87 , Issue.6 , pp. 485-492
    • Satterwhite, J.1    Heathman, M.2    Miller, P.D.3    Marín, F.4    Glass, E.V.5    Dobnig, H.6
  • 78
    • 0030897225 scopus 로고    scopus 로고
    • Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers
    • Mar
    • Schwietert HR, Groen EW, Sollie FA, Jonkman JH., Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther. 1997 Mar; 61 (3): 360-6.
    • (1997) Clin Pharmacol Ther. , vol.61 , Issue.3 , pp. 360-366
    • Schwietert, H.R.1    Groen, E.W.2    Sollie, F.A.3    Jonkman, J.H.4
  • 79
    • 0141796739 scopus 로고    scopus 로고
    • The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
    • Sep
    • Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM., The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep; 349 (13): 1216-26.
    • (2003) N Engl J Med. , vol.349 , Issue.13 , pp. 1216-1226
    • Finkelstein, J.S.1    Hayes, A.2    Hunzelman, J.L.3    Wyland, J.J.4    Lee, H.5    Neer, R.M.6
  • 80
    • 77951644239 scopus 로고    scopus 로고
    • Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
    • Apr
    • Finkelstein JS, Wyland JJ, Lee H, Neer RM., Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr; 95 (4): 1838-45.
    • (2010) J Clin Endocrinol Metab. , vol.95 , Issue.4 , pp. 1838-1845
    • Finkelstein, J.S.1    Wyland, J.J.2    Lee, H.3    Neer, R.M.4
  • 81
    • 33845370793 scopus 로고    scopus 로고
    • Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    • Jan
    • Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH., Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007 Jan; 18 (1): 59-68.
    • (2007) Osteoporos Int. , vol.18 , Issue.1 , pp. 59-68
    • Miller, P.D.1    Schwartz, E.N.2    Chen, P.3    Misurski, D.A.4    Krege, J.H.5
  • 86
    • 36849048891 scopus 로고    scopus 로고
    • Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study
    • Adachi JD, Hanley DA, Lorraine JK, Yu M., Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther. 2007; 29: 2055-69.
    • (2007) Clin Ther. , vol.29 , pp. 2055-2069
    • Adachi, J.D.1    Hanley, D.A.2    Lorraine, J.K.3    Yu, M.4
  • 87
    • 67349206106 scopus 로고    scopus 로고
    • Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    • Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH., Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009; 20: 943-8.
    • (2009) Osteoporos Int. , vol.20 , pp. 943-948
    • Lindsay, R.1    Miller, P.2    Pohl, G.3    Glass, E.V.4    Chen, P.5    Krege, J.H.6
  • 88
    • 72449146207 scopus 로고    scopus 로고
    • Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)
    • Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljnggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F., Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 2009; 85: 484-93.
    • (2009) Calcif Tissue Int. , vol.85 , pp. 484-493
    • Langdahl, B.L.1    Rajzbaum, G.2    Jakob, F.3    Karras, D.4    Ljnggren, O.5    Lems, W.F.6    Fahrleitner-Pammer, A.7    Walsh, J.B.8    Barker, C.9    Kutahov, A.10    Marin, F.11
  • 91
    • 62149099988 scopus 로고    scopus 로고
    • Persistence with teriparatide in postmenopausal osteoporosis; Impact of a patient education and follow-up program: The French experience
    • Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C., Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009; 20: 625-30.
    • (2009) Osteoporos Int. , vol.20 , pp. 625-630
    • Briot, K.1    Ravaud, P.2    Dargent-Molina, P.3    Zylberman, M.4    Liu-Leage, S.5    Roux, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.